Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 327 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

327 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 327 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

327 programs

Clinical programs

Page 2 of 7

  1. CS-1103

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 1 small molecule completed

    1 trial

  2. CVL-354

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  3. CVL-354

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  4. Cannabidiol, Medium Dose

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 1 small molecule active

    1 trial

  5. Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    2 trials

  6. Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Intoxication

    phase 1 small molecule active

    2 trials

  7. Cannabis Cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule completed

    1 trial

  8. Cannabis sativa Extract

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 1 small molecule active

    1 trial

  9. Carbon Monoxide inhalation

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 1 small molecule terminated

    1 trial

  10. Cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoker

    phase 1 small molecule completed

    1 trial

  11. Clarithromycin

    BRIGHT MINDS BIOSCIENCES INC.

    Drug-induced QT Prolongation

    phase 1 small molecule completed

    1 trial

  12. Clavulanic Acid

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence, in Remission

    phase 1 small molecule completed

    1 trial

  13. Clavulanic acid

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  14. Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    3 trials

  15. Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 small molecule completed

    1 trial

  16. Cocaine (IV)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule active

    1 trial

  17. Cocaine Self-adminstration

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  18. Cocaine hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Induced Sympathoexciation and Vasoconstriction

    phase 1 small molecule terminated

    1 trial

  19. Cognitive-Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 1 other completed

    1 trial

  20. Cohort 1 - TMP-301

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  21. Cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    phase 1 small molecule completed

    1 trial

  22. Cypep-1

    BRIGHT MINDS BIOSCIENCES INC.

    Cutaneous Warts

    phase 1 small molecule completed

    1 trial

  23. DF-003

    BRIGHT MINDS BIOSCIENCES INC.

    ROSAH

    phase 1 small molecule active

    1 trial

  24. Dabigatran

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 1 small molecule terminated

    1 trial

  25. Delta-9-THC Low Dose

    BRIGHT MINDS BIOSCIENCES INC.

    Age-related Cognitive Decline

    phase 1 small molecule active

    1 trial

  26. Dihydrexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule active

    1 trial

  27. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  28. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  29. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  30. Dofetilide

    BRIGHT MINDS BIOSCIENCES INC.

    Drug-induced QT Prolongation

    phase 1 small molecule completed

    1 trial

  31. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  32. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Disorder

    phase 1 small molecule terminated

    1 trial

  33. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 1 small molecule active

    1 trial

  34. Drug A (Blinded Drug)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule on hold

    1 trial

  35. EBC-129

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumours

    phase 1 small molecule active

    1 trial

  36. ECHO (Empowering Our Community & Health Outcomes)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 1 other terminated

    1 trial

  37. ECIG liquid vehicles

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Exposure

    phase 1 other completed

    1 trial

  38. ENA-001

    BRIGHT MINDS BIOSCIENCES INC.

    Respiratory Depression

    phase 1 small molecule active

    1 trial

  39. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  40. ETC-1907206

    BRIGHT MINDS BIOSCIENCES INC.

    Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 1 small molecule terminated

    1 trial

  41. ETC-1922159

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumors

    phase 1 small molecule active

    1 trial

  42. Empagliflozin 10 MG Oral Tablet [Jardiance]

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  43. Epidiolex

    BRIGHT MINDS BIOSCIENCES INC.

    CBD

    phase 1 small molecule active

    1 trial

  44. Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Use Disorder

    phase 1 other active

    1 trial

  45. Evolocumab

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Subjects

    phase 1 mab completed

    1 trial

  46. F2F

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Stimulant Misuse

    phase 1 other active

    1 trial

  47. FAVICOVIR 200 mg Film Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  48. FAVIR 200 MG FT

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

327 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.